1. Home
  2. HCKT vs TLSI Comparison

HCKT vs TLSI Comparison

Compare HCKT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hackett Group Inc (The).

HCKT

Hackett Group Inc (The).

HOLD

Current Price

$13.08

Market Cap

324.6M

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.51

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCKT
TLSI
Founded
1991
2010
Country
United States
United States
Employees
N/A
102
Industry
Professional Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.6M
270.2M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
HCKT
TLSI
Price
$13.08
$4.51
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$17.00
$7.00
AVG Volume (30 Days)
217.4K
137.9K
Earning Date
05-05-2026
05-14-2026
Dividend Yield
3.73%
N/A
EPS Growth
N/A
N/A
EPS
0.46
N/A
Revenue
$285,862,000.00
N/A
Revenue This Year
$2.55
$35.45
Revenue Next Year
$5.07
$37.58
P/E Ratio
$28.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.19
$3.42
52 Week High
$26.74
$7.95

Technical Indicators

Market Signals
Indicator
HCKT
TLSI
Relative Strength Index (RSI) 45.96 53.50
Support Level $12.42 $4.28
Resistance Level $14.67 $4.83
Average True Range (ATR) 0.52 0.23
MACD 0.00 0.03
Stochastic Oscillator 34.88 55.67

Price Performance

Historical Comparison
HCKT
TLSI

About HCKT Hackett Group Inc (The).

The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: